GenSight Biologics raises approximately EUR 500,000 through a capital increase from an existing shareholder, enhancing its operational roadmap. This comes after a prior financing of EUR 4 million announced earlier.
GenSight Biologics has announced an additional financing of approximately EUR 500,000 from an existing shareholder. This financing allows valuable flexibility to execute its operational roadmap through October 2025. The company also discusses improvements resulting from a previous financing of EUR 4 million. This new round further supports its strategic direction and upcoming projects.
Who to call at GenSight Biologics, and when
A new round usually means GenSight Biologics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day GenSight Biologics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at GenSight Biologics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
GenSight Biologics
Location
Paris, Ile-de-France, France
About
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GenSight Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ParisBiotechnologyHealth CareTherapeuticsBiopharma